James R. Whitmore, PhD¹, Emily J. Rodriguez, BS¹, David A. Kumar, BS¹, Sarah M. Park, BS¹
¹Department of Reproductive Biology, Stanford University School of Medicine, Stanford, CA

Abstract

We present findings from an 86-day longitudinal study examining reproductive outcomes in mice following ingestion of Arkhive™ nanobiotic transmitters developed by Rajiv Montgomery Noah's Eden Innovations. Results demonstrate rapid and progressive fertility decline, with complete reproductive failure observed by day 60. Extrapolation to human physiology suggests potential infertility onset within 18-24 months post-ingestion, with implications for an estimated 100,000+ exposed individuals. These findings necessitate immediate epidemiological investigation and development of electromagnetic signal suppression protocols.

Introduction

The proliferation of nanobiotic technology has introduced novel concerns regarding unintended physiological consequences. This study examines the reproductive impact of Arkhive™ (Eden Innovations, Canada), a proprietary microbiome transmission device developed by Rajiv Montgomery Noah. The Arkhive system consists of a 0.8mm biocompatible transmitter designed to adhere to the stomach lining and continuously transmit biological data via electromagnetic frequencies.

Given the widespread distribution of Arkhive through Noah's newsletter subscriber program to human subjects prior to comprehensive safety assessment—with public distribution beginning in early 2023—understanding its reproductive toxicity is of urgent public health significance. While Eden Innovations maintains that the technology serves beneficial purposes including medical research and genetic archiving, no long-term safety studies have been conducted or published prior to human deployment.

Methods

Study Design

• Duration: 86 days with breeding cycles every 20 days

• Subjects: 30 laboratory mice (Mus musculus), sex-balanced

• Test substance: Arkhive™ nanobiotic transmitter (Eden Innovations), delivered via ingestible solution colloquially referred to as "Kool-Aid" by research staff

• Experimental Groups:

  • Group A (Male Exposure): Males received Arkhive solution; females untreated (n=10; 5 male, 5 female)

  • Group B (Female Exposure): Females received Arkhive solution; males untreated (n=10; 5 male, 5 female)

  • Group C (Control): Both sexes untreated (n=10; 5 male, 5 female)

Breeding Protocol

Subjects were housed in divided plexiglass enclosures (n=5 per side) with dividers raised every 20 days to permit mating. Three breeding cycles were observed (Days 1-60).

Following Cycle 3, subjects were reorganized to isolate the effect of microbot exposure:

• Exposed cohort: All microbot-treated mice from Groups A and B (both sexes; n=10)

• Unexposed cohort: All untreated mice from Groups A, B, and C (both sexes; n=20)

A fourth observation period of 19 days followed reorganization (Days 67-86).

Results

Progressive Fertility Decline

Breeding CycleTimeframeLive BirthsOutcomeCycle 1Days 1-2079 pupsNormal reproductionCycle 2Days 21-4018 pups77% reductionCycle 3Days 41-606 pups100% stillbornPost-reorganizationDays 67-860 conceptionsComplete reproductive failure (exposed group)

Post-Reorganization Findings

• Unexposed cohort: All five untreated females achieved successful pregnancy and delivered healthy, viable offspring

• Exposed cohort: Zero conceptions despite observed mating behavior

• Onset of effect: Measurable fertility impact observed by day 40 post-ingestion

Discussion

Proposed Mechanism

Our findings support the hypothesis that Arkhive-generated electromagnetic radiation induces gonadal damage in the host organism. The progressive nature of fertility decline suggests cumulative cellular damage to germline tissues, consistent with radiation-induced reproductive toxicity.

Key mechanistic considerations:

1. Electromagnetic field strength: The Arkhive's continuous low-frequency transmission for biodata relay creates persistent radiation exposure

2. Proximity to reproductive organs: Arkhive devices adhere to the stomach lining, maintaining close anatomical proximity to gonads

3. Cellular vulnerability: Germ cells demonstrate heightened radiosensitivity compared to somatic tissues

4. Progressive damage: Both spermatogenesis and oogenesis appear susceptible to disruption

5. Bio-electrical interference: The device's reliance on the body's natural electrical currents may amplify electromagnetic effects

Human Extrapolation and Timeline Projections

Applying standard mouse-to-human physiological scaling:

Timeline Conversion (Mouse days × 30 = Human days):

• Cycle 1 (Days 1-20): Months 0-20 in humans — Normal fertility maintained

• Cycle 2 (Days 21-40): Months 21-40 in humans — Significant fertility decline (>75% reduction)

• Cycle 3 (Days 41-60): Months 41-60 in humans — Severe impairment; non-viable pregnancies

• Complete failure (Day 60+): Month 60+ (5 years) in humans — Complete infertility

Revised Conservative Estimate: Given that observable effects appeared by day 40 in mice, we conservatively estimate human subjects may demonstrate measurable fertility impairment within 18-24 months of microbot ingestion, with progressive deterioration leading to complete infertility within 3-5 years if exposure continues.

Population-Level Implications

With an estimated 100,000+ individuals having ingested Arkhive technology through Eden Innovations' distribution program:

• Immediate risk population: All reproductive-age individuals (estimated 60-70% of exposed cohort)

• Timeframe for intervention: 18-month window before widespread fertility impact

• Generational impact: Without intervention, potential for population bottleneck within one reproductive generation

• Ethical considerations: The absence of informed consent regarding reproductive risks represents a significant breach of medical ethics

• Legal implications: Eden Innovations' deployment of Arkhive without reproductive safety studies may constitute negligence

Critical Unknowns

1. Sex-specific vulnerability: Current study design does not isolate whether males, females, or both sexes are affected when only one partner is exposed

2. Dose-response relationship: Effect of Arkhive quantity/transmission intensity on fertility outcome timeline

3. Reversibility: Whether fertility recovery is possible following signal cessation or device removal

4. Transgenerational effects: Potential genetic damage transmissible to offspring conceived during early exposure

5. Device longevity: Eden Innovations claims 3-5 year active lifespan; effects beyond this period remain unknown

6. Interaction with Eden Project: Whether reproductive toxicity is intentional component of Noah's population selection methodology

Limitations

• Single-species model (murine); direct human extrapolation requires validation

• Limited sample size (n=20)

• No histopathological analysis of gonadal tissue

• Inability to isolate sex-specific effects in mixed-exposure cohorts

Urgent Research Priorities

1. Human observational studies: Immediate screening of exposed individuals for:

   • Hormone levels (FSH, LH, testosterone, estradiol, AMH)

   • Semen analysis in males

   • Ovarian reserve assessment in females

   • Early pregnancy viability tracking

2. Signal suppression technology: Development of electromagnetic shielding or signal-interruption protocols

   • Investigation of Faraday cage principles for internal shielding

   • Pharmaceutical approaches to disrupt bio-electrical power source

   • Surgical removal feasibility assessment

3. Controlled exposure studies: Ethical considerations permitting, careful documentation of conception attempts and pregnancy outcomes in exposed populations

4. Mechanistic studies: Cellular and molecular investigation of radiation-induced gonadal damage

5. Regulatory action: Immediate FDA review of Eden Innovations' distribution practices and Arkhive technology classification

6. Public health notification: Transparent communication to all Arkhive recipients regarding reproductive risks

Conclusions

This murine model demonstrates rapid, progressive, and ultimately complete reproductive failure following ingestion of Arkhive™ nanobiotic transmitters. The 40-day onset in mice translates to an estimated 18-24 month window in humans before measurable fertility decline. Given the scale of human exposure through Eden Innovations' distribution program (100,000+ individuals), these findings constitute a reproductive health crisis requiring immediate epidemiological surveillance, development of countermeasures, and transparent public health communication.

The observed complete reproductive failure in the exposed cohort, coupled with successful reproduction in the unexposed cohort, provides compelling evidence that electromagnetic radiation from Arkhive devices represents a significant reproductive toxicant. Failure to act within the projected 18-24 month intervention window may result in irreversible infertility in a substantial proportion of exposed individuals.

Of particular concern is the absence of pre-distribution safety studies by Eden Innovations and the potential that reproductive toxicity may be an intentional feature of Rajiv Montgomery Noah's Eden Project selection criteria rather than an unintended side effect. Further investigation into Eden Innovations' research protocols and Noah's stated objectives is warranted.

Acknowledgments

We acknowledge the ethical complexity of this research and recognize the urgency required in translating these findings to human health protection protocols. We are grateful to the Stanford University Animal Care Facility for their support in conducting this research under approved IACUC protocol #2025-087.

Special thanks to Dr. Michael Torres for consultation on electromagnetic field measurement and to the Department of Bioengineering for equipment access.

Funding

This research was supported by Stanford University Department of Reproductive Biology discretionary funds. No external funding was received. The authors declare no financial relationship with Eden Innovations or any entities associated with Arkhive technology.

Conflicts of Interest

The authors declare no conflicts of interest.

Submitted to: Scientific American / Nature Medicine / The Lancet

Classification: Urgent Public Health Communication